Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Two oleanane triterpenoids with a C-4 methyl substitution from Camellia oleifera Abel and their anti-inflammatory activities.

Created on 22 Jul 2026

Authors

Qing Li, Yijie Li, Chengqin Liang, Qijun Fan, Rui Huang, Binghai Lou, Jiangke Qin

Published in

Natural product research. Pages 1-11. Jul 21, 2026. Epub Jul 21, 2026.

Abstract

Two previously undescribed oleanane-type triterpenoids, 16α,22α,23,28-tetrahydroxyolean-12-en-3-one (1) and 4α-methyl-16α,21β,22α, 27-tetrahydroxyolean-12-en-3-one (2), together with three known analogues (3-5), were isolated from the seed cake of Camellia oleifera Abel. Their molecular structures were determined by NMR, HRMS and X-ray crystallography. Compound 2 features a rare C-4 monomethyl substitution. The anti-inflammatory activity of all compounds was evaluated in LPS-induced RAW264.7 macrophages. They dose-dependently inhibited the production of IL-6, NO, PGE2, and TNF-α without obvious cytotoxicity. Compound 4 exhibited the most potent broad-spectrum inhibition, while compounds 2 and 3 showed selective suppression of IL-6 and TNF-α, respectively. These findings expand the chemical diversity of triterpenoids from C. oleifera seed cake and highlight its potential as a source of anti-inflammatory lead compounds. The rare C-4 methylated skeleton of compound 2 provides new insights into structure-activity relationships among oleanane-type triterpenoids.

PMID:
42480108
Bibliographic data and abstract were imported from PubMed on 22 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement